Carey Danis & Lowe Investigates Alleged Risperdal Side Effect Male Breast Growth

Share Article

A pharmaceutical product liability litigation firm, Carey Danis & Lowe, is currently investigating an alleged Risperdal side effect, male breast growth. In February, the law firm launched an online Risperdal information center.

Carey Danis & Lowe | Pharmaceutical Product Liability Litigation

Carey Danis & Lowe | Pharmaceutical Product Liability Litigation

For more information about Risperdal and the legal services offered by Carey Danis & Lowe, contact the St. Louis law firm by phone at 800.721.2519.

The St. Louis pharmaceutical lawyers at Carey Danis & Lowe are currently investigating an alleged Risperdal side effect, male breast growth, medically termed gynecomastia. Carey Danis & Lowe represents plaintiffs who have filed lawsuits against Risperdal manufacturer, Janssen Pharmaceuticals, an arm of Johnson & Johnson, claiming that the anti-psychotic drug caused male breast growth, especially in adolescent male patients.

Risperdal won U.S. Food and Drug Administration (FDA) approval in 1993 to treat schizophrenia, and was later approved to treat bi-polar disorder.

Online Risperdal Resource
In February, Carey Danis & Lowe launched an online resource that supplies information about Risperdal and alleged side effect, gynecomastia. This online resource is available 24/7 to those interested in learning more about Risperdal and its potential impact on patient health and safety.

Risperdal Lawsuit History
In 2012, Johnson & Johnson settled five lawsuits in the Philadelphia Court of Common Pleas in which the plaintiffs alleged that use of Risperdal led to gynecomastia. Furthermore, these plaintiffs claimed that Johnson & Johnson deceptively marketed Risperdal, creating a deceitful facade that the anti-psychotic drug was safe for adolescent consumption.

One of the five cases settled in 2012 includes A.B., a minor vs. Janssen Pharmaceuticals, case number 00649, January Term 2010.*

The active Risperdal case in the Philadelphia Court of Common Pleas is In re: Risperdal Litigation, case number 100300296, and is being overseen by Judge Arnold L. New. There are currently over 350 pending Risperdal cases in the Philadelphia court.**

Legal Services for Alleged Victims of Risperdal
For more information about Risperdal and the legal services offered by Carey Danis & Lowe, contact the St. Louis law firm by phone at 800.721.2519.

About Carey Danis & Lowe

Carey Danis & Lowe is a plaintiff's litigation firm based in St. Louis, Missouri with law offices across the United States in Illinois, Missouri, and Florida. Carey Danis & Lowe specializes in defective drug and pharmaceutical litigation and class action lawsuits. The Carey Danis & Lowe team is comprised of experienced attorneys working alongside knowledgeable and professional staff that includes medical doctors, nurses, and information technology specialists. Contact Carey Danis & Lowe at 800-721-2519 for more information about our legal services.

Source

  • Bloomberg, Johnson & Johnson Agrees to Settle Five Rispersal [sic] Suits, October 4, 2012: http://bloom.bg/1fPAAJC

** Philadelphia Court of Common Pleas Trial Division, Risperdal Case List: http://www.courts.phila.gov/apps/clc/caselist.asp?search=Risperdal

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Scott Godar
Visit website